In an interview with CNN’s Chief Health Reporter Sanjay Gupta, Bourla said he first learned about the results of Sunday’s trial and that he has yet to see the data, pouring a splash of cold water when he thinks yes any political motive behind releasing news after voters. in the United States have chosen their candidate for the presidency.
Pfizer was temporarily reviewing data during its vaccine testing, but they didn’t have enough infections in the test group to get any meaningful data – until Sunday, Gupta reported. fox. If anything, the data arrives earlier than expected: In October, Bourla commented in an open letter on Pfizer’s website, saying: “Based on the current rate of registration and trial of We, we estimate we will reach this milestone in the third week of November. “
The Trump administration was quick to take note of Pfizer̵
7;s promising news. Vice President Mike Pence tweeted that Pfizer’s growth was “thanks to a public-private partnership created by President Donald Trump.”
However, Pfizer is not part of the Trump administration’s “Campaign Speed Campaign”, which has provided the impetus for pharmaceutical companies to step up development of the coronavirus vaccine.
The US federal government promised 1.95 billion dollars to Pfizer (PFE) and partner BioNTech (BNTX) to support vaccine delivery when it is ready – but the government is not directly working to help develop vaccines.
Trump called for pharmaceutical companies, pressuring them to make new developments ahead of Election Day. He has made it clear to the CEOs of the companies that he wants to see vaccines move faster than some of his health advisers think makes sense, CNN reported.
On Monday morning, President-elect Joe Biden issued a statement welcoming the “good news” and congratulated “the outstanding women and men who helped make the breakthrough.”
He added that “it is also important to understand that the end of the battle against Covid-19 is still months away” and that “there will be many more months before a wide vaccination” is available in the United States.
Dr Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, said the news of Pfizer’s vaccine bodes well for other Covid-19 vaccines in development, adding that Pfizer could Results are rapid due to the severity of the pandemic.
Manufacture of vaccines
Although the vaccine did not soon become widely available, Pfizer said it plans to get emergency approval from the U.S. Food and Drug Administration as soon as the volunteers are follow up for two months after second dose of vaccine.
Pfizer has at least three vaccine production facilities in the United States, Gupta said. At the Kalamazoo facility, Michigan, there are several refrigerators – the length of a football field – that are used to preserve vaccines.
For months, companies have been racing to develop, and eventually deliver an effective coronavirus vaccine. The race shows no signs of slowing down as companies continue to move their vaccine candidates through clinical trials, getting closer and closer to determining which vaccines are deemed safe and effective.
The Pfizer and Moderna vaccine uses new technology that has never been used in vaccines before, and experts say it is a reason for caution.
While the developments mean progress is being made, there is not much they will do to minimize the short winter coronavirus increase provided that it will take place by 2021 before the dose. Medication is available to all Americans.
CNN’s Maggie Fox, Sara Murray and Kevin Liptak contributed to this report.